Resistance to human immunodeficiency virus type 1 protease inhibitors.
Boden
D
D
Aaron Diamond AIDS Research Center, New York, New York 10016, USA.
Markowitz
M
M
D002219:Carbamates; D004351:Drug Resistance; D005663:Furans; D016333:HIV Protease / Q000737:chemistry / Q000502:physiology; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D019469:Indinavir / Q000494:pharmacology; D019888:Nelfinavir / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D011753:Pyrones / Q000494:pharmacology; D019438:Ritonavir / Q000494:pharmacology; D019258:Saquinavir / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000494:pharmacology
D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; C095108:amprenavir; D019469:Indinavir; D016333:HIV Protease; D019888:Nelfinavir; D019258:Saquinavir; D019438:Ritonavir; C107201:tipranavir